ReviewOncotarget2017
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed.
- Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging Opportunities.Molecules (Basel, Switzerland) · 2026Review
- TRIM28-Derived Peptide Exerts Anti-Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin.Medical oncology (Northwood, London, England) · 2026Article
- Therapeutic Potential of Allomyrinasin in Oral Squamous Cell Carcinoma via Decreased NBC Activity.Pharmaceutics · 2026Article
- Functional characterization of HR-CATH2, a novel cathelicidin fromZoological research · 2026Article
- A Comprehensive Review on the Anticancer Activity of Plant Peptides and Their Mechanisms of Action.Foods (Basel, Switzerland) · 2026Review
- Article
- Design and Evaluation of the Antibacterial Peptide FK18: a Therapeutic Approach for Mastitis in Dairy Animals.Probiotics and antimicrobial proteins · 2026Article
- Anticancer Bioactive Peptides from Plants: Sources, Action Mechanisms, and Potential Superiority to Conventional Chemotherapy.Probiotics and antimicrobial proteins · 2026Review
- Physicochemical Characteristics of Amphipathic Peptides and Their Cytotoxic Effects on Cancer and Normal Cell Lines.International journal of molecular sciences · 2026Article
- Pep5-Cpp, a Cyclin D2-Derived Antimicrobial.Molecules (Basel, Switzerland) · 2026Article
- Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).Oncology reports · 2026Review
- The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncology research · 2026Review
- Integrating a cationic backbone with a hydrophobic core: A structure-function strategy for designing self-assembling antimicrobial peptides with enhanced activity.Zoological research · 2025Article
- Investigating SMR Peptide Interactions with Breast Cancer-Associated Proteins.International journal of molecular sciences · 2025Article
- Marine-Derived N-Terminal Mitochondrial-Targeting Sequences Exhibit Antimicrobial and Anticancer Activities.International journal of molecular sciences · 2025Article
- Insights into Membrane Damage byBiomolecules · 2025Article
- Harnessing multifunctional HBc virus-like particles for safe and effective delivery of melittin in cancer therapy.Nanomedicine (London, England) · 2025Article
- Cationic antimicrobial peptide CC34 potential anticancer and apoptotic induction on cancer cells.Amino acids · 2025Article
- CancerPPD2: an updated repository of anticancer peptides and proteins.Database : the journal of biological databases and curation · 2025Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the last several decades, there have been significant advances in anticancer therapy. However, the development of resistance to cancer drugs and the lack of specificity related to actively dividing cells leading to toxic side effects have undermined these achievements. As a result, there is considerable interest in alternative drugs with novel antitumor mechanisms. In addition to the recent approach using immunotherapy, an effective but much cheaper therapeutic option of pharmaceutical drugs would still provide the best choice for cancer patients as the first line treatment. Ribosomally synthesized cationic antimicrobial peptides (AMPs) or host defense peptides (HDP) display broad-spectrum activity against bacteria based on electrostatic interactions with negatively charged lipids on the bacterial surface. Because of increased proportions of phosphatidylserine (negatively charged) on the surface of cancer cells compared to normal cells, cationic amphipathic peptides could be an effective source of anticancer agents that are both selective and refractory to current resistance mechanisms. We reviewed herein the prospect for AMP application to cancer treatment, with a focus on modes of action of cationic AMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.